• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • Australia
      North America
      World
    Login

    Investing News NetworkYour trusted source for investing success

    • North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Metals
    Tech
    Life Science
    Life Science Market
    Life Science News
    Life Science Stocks
    • Life Science Market
    • Life Science News
    • Life Science Stocks

    FDA Approves Start of Innovative On-Ambulance Phase 2 Clinical Trial for Treatment of Acute Stroke by Diffusion Pharmaceuticals

    Gabrielle Lakusta
    Sep. 12, 2018 08:56AM PST
    Life Science Investing News

    Diffusion Pharmaceuticals (Nasdaq:DFFN), a cutting-edge biotechnology company developing new treatments for life-threatening medical conditions by improving the body’s ability to bring oxygen to the areas where it’s needed most, announced today that it has received FDA approval to enroll patients in an ambulance-based Phase 2 clinical trial testing its lead drug, trans sodium crocetinate (TSC), for the …

    Diffusion Pharmaceuticals (Nasdaq:DFFN), a cutting-edge biotechnology company developing new treatments for life-threatening medical conditions by improving the body’s ability to bring oxygen to the areas where it’s needed most, announced today that it has received FDA approval to enroll patients in an ambulance-based Phase 2 clinical trial testing its lead drug, trans sodium crocetinate (TSC), for the treatment of acute stroke.

    As quoted in the press release:

    The trial, named PHAST-TSC (Pre-Hospital Ambulance Stroke Trial-TSC), will involve 23 hospitals across urban, suburban, and rural areas in Los Angeles and Central Virginia, working closely with approximately 150 emergency medical transport groups. Results for the PHAST-TSC trial could be available in just under two years – a critically fast turnaround for this potential improvement in the front-line medical treatment of stroke, which afflicts nearly 800,000 Americans each year at an estimated cost of over $34 billion to the U.S. economy.

    Nearly two million brain cells die each minute during a stroke. As a result, medical providers seek to provide treatment for patients as quickly as possible during the hours immediately after stroke onset. TSC, which will be administered by paramedics while the stroke victim is still in the ambulance, may offer new hope for these patients by increasing the amount of oxygen directed to affected tissue, potentially reducing cell death and improving patient outcomes. In addition to stroke, TSC has shown safety and efficacy to date in oncology, with a Phase 3 trial in glioblastoma (GBM) brain cancer currently enrolling.

    Click here to read the full press release.

    fda approvalnasdaq:dffndiffusion pharmaceuticals
    The Conversation (0)
    Go Deeper
    AI Powered
    Microscopic view of stem cells.

    Stem Cell Stocks: 10 Biggest NASDAQ Companies in 2025

    Pharma Outlook

    Pharma Outlook

    Latest News

    Outlook Reports

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Stocks

    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES
    ×